A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma

NCT04486781 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Urothelial Carcinoma

Interventions

DRUG: Pembrolizumab + sEphB4-HSA

Sponsor

Vasgene Therapeutics, Inc